Featured Articles

  1. How Cidara Got Its Molecule Back 10/30/2024

    In a dramatic turn of events that makes for some great storytelling, Cidara's novel drug-Fc conjugate, once locked up in a deal with J&J, is now squarely back in the biotech's hands and moving forward with an aggressive phase 2b study.

  2. Now Is The Time For Philanthropic Venture Capital 10/25/2024

    Longer time horizons and therapeutic area expertise make philanthropy venture capital an attractive option for biopharmaceutical companies developing new products. It can also de-risk funding rounds by helping to bring in additional investors.

  3. AI, PoS, And ROI: An Alphabet Soup Of 21st Century Drug Development 10/23/2024

    Part two of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI tools improve the probability of success and likelihood of drug approval.

  4. Why Job Rotations Are Critical To Shaping Tomorrow's Leaders 10/22/2024

    Job rotations provide an opportunity for promising, high-potential employees to grow and learn new parts of the business. Kristina Fusella describes the challenges and multifactorial benefits of job rotations as a tool for leadership development at Novo Nordisk.

  5. Companies To Watch: Spinogenix 10/18/2024

    Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, glaucoma, and Fragile X syndrome.

  6. Efficiency Is The New Normal 10/11/2024

    Despite groundbreaking innovations, biopharmaceutical companies have struggled to keep pace with capital markets, underscoring the importance of not only scientific innovation but also the need for efficient strategies to drive value growth.

  7. Leading Through Adversity: How Putting People First Drives Success 10/8/2024

    In the second article in a series on the leadership benefits of putting employees first, Christine Miller, president and CEO of Melinta Therapeutics, describes the challenges, actions, and experiences she faced as a new CEO.

  8. AI, PoS, And ROI: An Alphabet Soup Of 21st Century Drug Development 10/4/2024

    Part one of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI tools improve the probability of success and likelihood of drug approval.

  9. Navigating The Cell And Gene Regulatory Landscape 10/3/2024

    Navigating the complex regulatory landscape is essential for cell and gene therapy success. Explore key considerations, challenges, and best practices for companies operating in this space.

  10. The Benefits And Risks Of An LLC Business Model In Biotech 10/3/2024

    An LLC model in biotech brings specific advantages, such as streamlined deal-making, IP ownership, and capital reinvestment and return. However, it won't work for every company, as Abbas Kazimi, chief business officer at Nimbus Therapeutics, explains.